Special Issue

Oxidative Stress and Antioxidant Therapy in Diseases

Message from the Guest Editors

Reactive Oxygen Species (ROS) are produced under normal physiological conditions in organisms and play a significant role in various biological functions, both beneficial and harmful. ROS can damage DNA, proteins, and lipids, leading to cellular dysfunction and disease. These reactive molecules are generated through both endogenous processes, such as cellular respiration, and exogenous sources, including UV radiation and environmental toxins. The body's antioxidant system, which includes enzymes like catalase and superoxide dismutase as well as vitamins and minerals, serves to neutralize ROS and protect against oxidative stress.

This Special Issue aims to explore how the assessment of antioxidants and oxidants can facilitate the early diagnosis and prevention of diseases linked to oxidative stress. We are particularly interested in studies that demonstrate how these assessments can be used to predict disease onset, monitor progression, and evaluate the effectiveness of therapeutic interventions.

Guest Editors

Dr. Evgenia Lymperaki

Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, Sindos, Greece

Dr. Ioannis Tsamesidis

Department of Biomedical Sciences, Faculty of Health Sciences, International Hellenic University, Sindos, 57400 Thessaloniki, Greece

Deadline for manuscript submissions

15 January 2026



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/211816

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

